two of the world’s foremost cancer researchers announced Tuesday the creation of a new drug aimed at preventing the growth of an array of cancers.
Tak Mak, director of the Family Institute for Breast Cancer Research at the Princess Margaret Cancer Centre, and Dr. Dennis Slamon, of the University of California Los Angeles, are part of the 100-person team that developed the drug, which has been tested on human ovarian, breast, pancreas, lung and colon cancer in mice.
The researchers are calling the drug a “sharpshooter” for its ability to target a specific enzyme, rather than take a “one-size fits all” approach, Slamon explained to reporters at a Toronto news conference.
Tak Mak, director of the Family Institute for Breast Cancer Research at the Princess Margaret Cancer Centre, and Dr. Dennis Slamon, of the University of California Los Angeles, are part of the 100-person team that developed the drug, which has been tested on human ovarian, breast, pancreas, lung and colon cancer in mice.
The researchers are calling the drug a “sharpshooter” for its ability to target a specific enzyme, rather than take a “one-size fits all” approach, Slamon explained to reporters at a Toronto news conference.
You must be registered for see links